Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Urogen Pharma, retaining the price target of $40.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily driven by the promising commercial trajectory of UroGen Pharma’s ZUSDURI. Since its launch, the drug has shown significant momentum with a growing number of activated care sites and prescribers. The recent assignment of a permanent J Code by CMS is expected to streamline reimbursement processes, potentially reducing the time from patient enrollment to authorization, which could further accelerate ZUSDURI’s market uptake.
Additionally, UroGen’s financial health supports this positive outlook, with the company on track to achieve cash flow-positive status by late 2026. Despite a slight miss in third-quarter revenue expectations, UroGen’s overall commercial execution aligns with forecasts, and the company maintains a strong cash position. The ongoing development of UGN-103, with promising clinical trial results, further bolsters the company’s future prospects, justifying the Buy rating and a 12-month price target of $40.
In another report released on November 7, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $55.00 price target.